Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Significant Decline in Short Interest

Autonomix Medical, Inc. (NASDAQ:AMIX) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 58,624 shares, a drop of 46.1% from the August 15th total of 108,801 shares. Currently, 6.4% of the company’s stock are short sold. Based on an average daily trading volume, of 4,225,824 shares, the days-to-cover ratio is presently 0.0 days.

Autonomix Medical Stock Down 2.1%

Shares of Autonomix Medical stock opened at $4.12 on Wednesday. The firm has a market capitalization of $4.00 million, a P/E ratio of -0.10 and a beta of -1.00. Autonomix Medical has a 52 week low of $2.44 and a 52 week high of $32.55. The firm’s 50 day moving average is $5.83 and its two-hundred day moving average is $7.26.

Autonomix Medical (NASDAQ:AMIX) last posted its earnings results on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. As a group, research analysts expect that Autonomix Medical will post -20.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on AMIX shares. Weiss Ratings upgraded shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a research report on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of Autonomix Medical from a “sell” rating to a “strong sell” rating in a report on Monday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.